Peter Vangheluwe

This study identifies ATP13A3-antizyme regulation as a mechanism for adaptive polyamine uptake in cancer, showing that targeting ATP13A3 with AMXT 1501 can block this response.

The paper shows ATP13A2 loss of function disrupts polyamine metabolism, leading to SAM depletion and epigenetic astrocyte toxicity, which contributes to Parkinson's disease.

This study shows that ATP10B loss causes dopaminergic neuron death and Parkinsonian symptoms in rats and human stem cell models.

This study identifies ATP13A3 as a polyamine transporter mediating DFMO-induced polyamine uptake in neuroblastoma, highlighting it as a therapeutic target.

This paper develops genetically encoded fluorescent sensors to measure polyamine levels, uptake, and distribution in cells, revealing compounds that modulate polyamine levels.

The paper functionally characterizes ATP13A2 variants linked to neurodegenerative disorders, finding that only the homozygous NCL variant causes complete loss-of-function, while others show subtle defects.